Sesamin is the major active ingredient is Sesamum indicum seeds. Several studies revealed that sesamin possesses potent anti-cancer properties. The anti-cancer effects of sesamin have been mainly attributed to its anti-proliferative, pro-apoptotic, anti-inflammatory, anti-metastatic, anti-and pro-angiogenic, and pro-autophagocytic activities. In this review, we provide a comprehensive summary of the reported anti-cancer effects of sesamin, both in vitro and in vivo. Experimental findings related to the potential of sesamin to attenuate oxidative stress, inflammation, proliferation, metastasis, and angiogenesis in various cancer cells and tumors are analyzed. Studies focusing on the ability of sesamin to induce apoptosis and autophagy in cancer cells are also underscored. Moreover, the molecular mechanisms underlying the anti-cancer effects of sesamin are highlighted, and the major signaling pathways targeted by sesamin are identified. Although the exact signaling events triggered by sesamin in cancer cells are not fully revealed, our analysis indicates that NF-κB, STAT3, JNK, ERK1/2, p38 MAPK, PI3K/AKT, caspase-3, and p53 signaling pathways are critically involved in mediating the anti-cancer effects of sesamin. In sum, the experimental evidence suggesting that sesamin could exert potent anti-cancer activities in vitro and in vivo is compelling. Hence, sesamin can potentially be employed as an effective adjuvant therapeutic agent in ameliorating tumor development and progression, and therefore, it could be used in the prevention and/or treatment of various types of cancer.
Introduction
The cure for cancer is one of the most pursued domains of research in the medical field. Studies show that the progression of the number of cancer cases will rise from 14 million in 2012 to 24 million in 2035 (Stewart et al., 2016) . The number of cancer-related deaths are presumed to rise from 8.2 million to 14.6 million annually (Stewart et al., 2016) . Consequently, cancer treatments are extensively being developed and implemented. Chemotherapy, radiotherapy, and surgical procedures are various methods that are widely used to treat cancer patients. Nevertheless, the approaches used to treat cancer are not just constraint to the experimental testing of synthetic chemicals. The use of different plants and natural products has also been given ample attention in the last two decades. Sesamin is one of the natural products that received considerable attention lately as a potential anti-cancer agent that could be used in the prevention and/or treatment of different types of cancer.
Sesamin is a fat-soluble lignan found in the flowering plant, sesame (Sesamum indicum). With a huge variation in abundance, sesamin if found in about 30 different plants belonging to different genera including Sesamum, Piper, Virola, Magnolia, and Camellia (Dar and Arumugam, 2013 ). Yet, S. indicum, the oilseed crop, serves as the major plant source for the acquirement of large amounts of sesamin (Dar and Arumugam, 2013) . Sesamum is a genus that belongs to the Pedaliaceae family (Zhang et al., 2013) . S. indicum is mainly grown and cultivated in Africa, China, India, and South America (Oyinloye et al., 2016) . Thus, S. indicum is found mostly in subtropical and tropical regions. S. indicum is one the oldest cultivated plants. Its agricultural use is dated back to more than 5000 years ago, in an Indian subcontinent known as Harappa Valley (Zhang et al., 2013) . The nutritional value of this plant is significant to humans as it contains high amounts of edible oils and proteins. Several studies investigated the therapeutic properties of S. indicum, and there is compelling in vitro and in vivo experimental evidence suggesting that this plant and its active ingredients possess hepatoprotective, hypoglycemic, anti-hypertensive, anti-estrogenic, and most relevant to this review, anti-cancer properties. It has also been demonstrated that S. indicum could be used in the treatment of Parkinson's disease (PD) (Oyinloye et al., 2016) . Moreover, sesamin and sesame oil have been shown to modulate macrophage cholesterol homeostasis, a major event in atherogenesis, leading to anti-atherogenic effects (Majdalaweh and Ro, 2014; Majdalawieh and Ro, 2015) . The numerous studies performed on this plant and its active ingredients revealed several properties that can potentially be employed to combat a wide range of diseases including, but not limited to, different types of cancer.
Sesamin is a furofuran type lignan that exhibits considerable effects on carbohydrate and lipid metabolism, hypertension, inflammation, and free radical scavenging (Dar and Arumugam, 2013; Stewart et al., 2016; Zhang et al., 2013) . The molecular formula of sesamin is C 20 H 18 O 6 and its molecular weight is 354.36 g/mol. The effects of sesamin against tumorigenesis have been tested on a number of cancer cell lines and animal models, and such studies revealed that sesamin could potentially be used as an anti-carcinogen. For example, in a recent study, the anti-cancer effects of sesamin were examined against cancer stem-like side population (SP) cells from gallbladder tumors generated in nude mice (Kong et al., 2014) . Sesamin treatment promoted the differentiation of SP cells into cells expressing E-cadherin (an epithelial marker). Sesamin suppressed the carcinogenic potential of SP cells with regard to tumor-sphere formation, colony-formation, and Matrigel invasion. Furthermore, sesamin weakened the drug-resistance property of SP cells and attenuated tumor growth both in vitro and in vivo (Kong et al., 2014) . Such anti-cancer effects of sesamin were attributed to its ability to significantly down-regulate the expression of nuclear factor κB (NF-κB), interleukin-6 (IL-6), phosphorylated signal transducer and activator of transcription (p-STAT3), transcriptional target of STAT3 (TWIST), and vimentin (a mesenchymal marker) (Kong et al., 2014) .
Some of the anti-cancer properties of sesamin are attributed to its anti-proliferative, pro-apoptotic, anti-inflammatory, anti-metastatic, anti-angiogenic, and pro-autophagocytic activities. Indeed, sesamin was showcased to regulate a number of signal transduction pathways that mediate oxidative stress, proliferation, apoptosis, inflammation, angiogenesis, and autophagy. These anti-carcinogenic effects of sesamin enable it to suppress the effects of cancer-inducing compounds. This is mainly achieved by directly targeting transformed cancerous cells or by blocking cellular mechanisms that are crucial for promoting tumorigenesis.
Herein, we provide a comprehensive review of the in vitro and in vivo anti-cancer effects of sesamin. This review showcases the capacity of sesamin to serve as a potent anti-carcinogen that can effectively attenuate tumor development and progression. The well-documented anti-proliferative, pro-apoptotic, anti-inflammatory, anti-metastatic, anti-angiogenic, and pro-autophagocytic activities of sesamin are underscored. The signaling pathways and mechanisms of action underlying the anti-cancer effects of sesamin are also highlighted and analyzed. Understanding the exact molecular mechanisms and signaling pathways that are targeted by sesamin to block tumor development and progression is crucial for our ability to potentially employ sesamin as a potent therapeutic agent in the prevention/treatment of different types of cancer.
Anti-proliferative effects of sesamin
One of the main characteristics underlying the tumor-suppressing and anti-cancer effects is its well-documented anti-proliferative potential. Sesamin was shown to significantly inhibit the proliferation of a wide variety of tumor cells including leukemia, multiple myeloma, and cancers of the colon, prostate, breast, pancreas, and lung (Harikumar et al., 2010) . Such anti-proliferative effects were demonstrated to be due, at least in part, to the ability of sesamin (25-100 μM) to potently block NF-κB signaling pathway, in a dose-and time-dependent manner, in several cell lines (Harikumar et al., 2010) . Indeed, sesamin had no significant effect on basal NF-κB activation, but it significantly suppressed tumor necrosis factor α (TNFα)-induced NF-κB activation in a dose-and time-dependent manner (Harikumar et al., 2010) . In another in vitro study, the ability of (-)-sesamin to inhibit proliferation of multidrug-resistant (MDR) tumor cells and cancer cell lines was investigated (Saeed et al., 2014) . MDR in tumors has been shown to be mediated by several glycoproteins including ATP-binding cassette (ABC) drug transporters ABCB1 and ABCB5, and hence, ABCB1-and ABCB5-overexpressing tumor cells display potent MDR. It was demonstrated that (-)-sesamin (0.01-1000 μM) significantly suppressed ABCB1 and ABCB5 expression in many cancer cell lines, and it significantly inhibited proliferation of ABCB1-and ABCB5-overexpressing MDR tumor cells. Such effects were dose-dependent. Indeed, the 50% inhibition concentrations (IC 50 ) of (-)-sesamin exhibited desirable effects in a panel of 55 cancer cell lines of the National Cancer Institute (NCI), including the NCI-60 cell line panel. After examining the mRNA sequence of NCI-60, 23 genes were identified to align with the IC 50 values that are displayed by (-)-sesamin. However, it was also concluded that sesamin could also mediate its anti-proliferative effects against MDR tumor cells independent of its ability to regulate cellular mechanisms that involve ABCB1 and ABCB5 activity (Saeed et al., 2014) . Consistently, other studies reported that sesamin regulates the expression of various ABC transporters, including ABCG5 and ABCG8 (Rogi et al., 2011) . Obviously, sesamin seems to possess differential anti-proliferative efficacy against different cancer cells. It would be useful if such differential efficacy can be further investigated to reveal the exact mechanisms underlying the anti-proliferative activity of sesamin in different types of tumors. This could enable us to better use sesamin as part of adjuvant therapy to prevent or treat different types of cancers.
Aside from its direct anti-proliferative activity, sesamin can also enhance the anti-proliferative capacity of other compounds exhibiting anti-cancer properties. γ-tocotrienol, a natural form of vitamin E, is a phytochemical that possesses potent anti-cancer potential. Given that sesamin enhances the half-life of γ-tocotrienol by inhibiting its metabolic degradation, Akl and colleagues investigated the possible ability of sesamin to synergistically boost the anti-proliferative effects of γ-tocotrienol against neoplastic mouse (+SA) and human (MCF-7 and MDA-MB-231) mammary cancer cell lines (Akl et al., 2013) . Although sesamin (10-150 μM) and γ-tocotrienol individually caused a significant dose-dependent suppression of the proliferation of all tested cancer cell lines, a mixture of both compounds caused synergistic antiproliferative effects. Importantly, such treatments had very little or no effect on the proliferation or viability of normal (mouse CL-S1 and human MCF-10A) mammary epithelial cells. It was further revealed that such effects of sesamin and γ-tocotrienol are due to induction of G1 cell cycle arrest, reduction of cyclin D1, cyclin-dependent kinase 2 (CDK2), CDK4, CDK6, phosphorylated retinoblastoma protein (p-RB), and E2 transcription factor 1 (E2F1) levels, and elevation of p27 and p16 levels. Moreover, the combined treatment did not induce apoptosis nor decreased the viability of the tested cancer cell lines. Interestingly, such effects were observed at very low, sub-effective doses of sesamin and γ-tocotrienol, suggesting that the synergistic effect of sesamin toward γ-tocotrienol-mediated anti-proliferative activity is not directly related to the ability of sesamin to inhibit the metabolic degradation of γ-tocotrienol (Akl et al., 2013) . Overall, this study reveals that the specific and synergistic anti-proliferative role of the combined treatment of sesamin and γ-tocotrienol against cancer cells is cytostatic and not cytotoxic. Indeed, an earlier study by the same group revealed that a combined treatment of sesamin (10-120 μM) and γ-tocotrienol, at sub-effective doses, in murine +SA mammary cancer cells significantly and dose-dependently abrogated EGF-induced phosphorylation of ErbB3 and ErbB4 receptors, which are over-expressed in many cancer cells and promote their proliferation. The mixture, which was added to the cultured cells for a 4-day period, also significantly decreased the intracellular levels of total and phosphorylated c-Raf, MAPK/ERK kinase 1/2 (MEK1/2), extracellular signal-regulated kinase 1/2 (ERK1/ 2), phosphoinositide-3-kinase (PI3K), phosphoinositide-dependent kinase 1 (PDK1), protein kinase B (PKB/AKT), p-NF-κB, Janus kinase 1 (JAK1), JAK2, and STAT1 in a dose-dependent manner (Akl et al., 2012) . Taken together, these findings suggest that a combinational therapy of sesamin and γ-tocotrienol could prove effective in vivo with regard to suppressing proliferation of cancer cells, and hence, it can used as an efficacious anti-cancer therapeutic approach to prevent or treat breast cancer. Additionally, an in vitro study by Yokota and colleagues explored the ability of sesamin to induce growth inhibition in human cancer cells, using human breast cancer cell line (MCF-7) as a model (Yokota et al., 2007) . It was demonstrated that sesamin (12.5-100 μM) caused a significant inhibition of MCF-7 cell proliferation in a dose-dependent manner. Further analysis revealed that sesamin caused a cell cycle arrest at the G1 phase by inducing the dephosphorylation of RB. The sesamin-mediated inhibition of cell proliferation was accompanied by enhanced proteasome degradation of cyclin D1, a critical proto-oncogene that is over-expressed in several cancer cells. The sesamin-mediated down-regulation of cyclin D1 is not restricted to MCF-7 cells as the same effect was observed in lung cancer cells, transformed renal cells, immortalized keratinocytes, melanoma, and osteosarcoma (Yokota et al., 2007) . The effects of sesamin on the proliferation of cancer cells were also tested in vivo. A study by Truan and colleagues established several roles that sesamin played in suppressing human estrogen receptor (ER)-positive breast tumors (MCF-7) in a murine model (Truan et al., 2012) . In this study, athymic mice were fed a control diet or a diet supplemented with sesamin (1 g/kg) for 8 wks. Mice that were fed a sesamin-supplemented diet showed a significant decrease (23%) in tumor size compared to their control counterparts. Indeed, sesamin significantly reduced tumor cell proliferation and increased apoptosis at high levels of circulating estrogen. Such effects were accompanied by decreased levels of epidermal growth factor receptor-2 (EGFR-2), endothelial growth factor receptor (EGFR), and downstream pMAPK. Sesamin, however, had no effect on the levels of insulin-like growth factor-1 receptor (IGF-1R), vascular endothelial growth factor receptor-2 (VEGFR-2), AKT, pAKT, or MAPK of the growth factor signaling pathway. This study also revealed that sesamin is a more potent inhibitor of mammary tumor growth compared to secoisolariciresinol diglucoside (SDG), a lignan in flaxseeds (Truan et al., 2012) . Furthermore, sesamin (10-100 μg/ml) was shown to significantly inhibit lipopolysaccharide (LPS)-induced proliferation of PC3 cells in a dose-and time-dependent manner (Xu et al., 2015) . This was accompanied by a dose-dependent decrease in LPS-induced expression of cyclin D1, cyclooxygenase-2 (COX-2), B cell lymphoma 2 (Bcl-2), and survivin (Xu et al., 2015) . (Fig. 1) Interestingly, stereoisomers of sesamin are shown to possess antiproliferative activities. For example, Freise and colleagues investigated the possible anti-proliferative activity of (+)-episesamin, a stereoisomer of sesamin, against human hepatocellular carcinoma (HCC) in an attempt to explain its anti-neoplastic effects (Freise et al., 2012) . To this end, three human HCC cell lines (HepG2, Huh-7, and SK-Hep) were treated for 24 h with (+)-episesamin (5-20 μM), isolated from an antifibrotic extract of the flowering plant Lindera obtusiloba. It was demonstrated that (+)-episesamin significantly and dose-dependently reduced the proliferation of HCC cells by about 50%, induced apoptosis, and suppressed invasion. Further analysis revealed that HCC cells treated with (+)-episesamin displayed dose-dependent suppression of basal and TNFα-induced NF-κB signaling as well as inhibited TNFα-and LPS-induced IL-6 expression (Freise et al., 2012) .
Pro-apoptotic effects of sesamin
The protective potential of sesamin against unregulated proliferation and tumorigenesis is substantially associated with its ability to induce apoptosis. In an in vitro study, Miyahara and colleagues demonstrated that sesamin and episesamin (20-100 μM) potently induced growth inhibition and apoptosis in human lymphoid leukemia Molt 4B cells in a dose-dependent manner (Miyahara et al., 2000) . In a dosedependent manner, exposure of Molt 4B cells to sesamin or episesamin was followed by formation of apoptotic bodies and fragmentation of DNA to oligonucleosomal-sized fragments, a hallmark of apoptosis. Such effects were observed 2 days and 3 days post treatment with sesamin and episesamin, respectively (Miyahara et al., 2000) . Similarly, sesamin (10-200 μg/ml) was shown to induce dose-dependent apoptosis in HL-60, U937, and Molt 4B cells with apoptotic character (condensed nuclei and apoptotic bodies) (Banjerdpongchai et al., 2010) . Sesamin (10-40 μg/ml) was also shown to elevate reactive oxygen species (ROS) level and caspase-3 activity, while decreasing mitochondrial transmembrane potential (MTP) in HL-60 cells in a dosedependent manner. Noteworthy, sesamin (10-40 μg/ml) had no effect on caspase-8 activity nor cytochrome c release even 4 h post treatment in HL-60 cells. It was concluded that the ER stress pathway is critically involved as sesamin (40 μg/ml) significantly increased the expression of GADD153 in a time-dependent manner in HL-60 cells (Banjerdpongchai et al., 2010) .
Correspondingly, Hibasami and colleagues investigated the anticancer effects of an aqueous extract of the stem bark of Acanthopanax senticosus HARMS (ASH) on KATO III cells, human stomach cancer cells . The cultivation of cells with ASH (23-90 μM) for 3 days caused marked growth inhibition and induction of apoptosis in a dose-and time-dependent manner. This pro-apoptotic effect was evident by the accumulation of oligonucleosomal-sized DNA fragments and apoptotic bodies. Further analysis revealed that among sesamin, chlorogenic acid, syringaresinol-di-O-beta-D-glucoside (SR), and syringin, components of the n-butanol extract of ASH, only sesamin was able to induce apoptosis in KATO III cells . Hence, the pro-apoptotic effects of ASH are attributed to the ability of sesamin to induce apoptosis. Such effects were dose-dependent. (Fig. 1) In another in vitro study, it was demonstrated that sesamin possesses protective effects against the growth of lung cancer cells (MRC-5, HEL299, H1299, A549, H1437, and 293 T cells) by triggering apoptotic events (Wang et al., 2010) . The study focused on the dose-dependent inhibitory effects of (-)-sesamin (10-200 μM) against Lon, a mitochondrial protease that is up-regulated in non-small cell lung cancer (NSCLC) cell lines and is critically involved in lung tumorigenesis. Indeed, suppression of Lon level and activity triggers caspase-3-mediated apoptosis. Molecular docking analysis revealed that (-)-sesamin interacts with Lys 898 residue in the active site of human Lon, suggesting that (-)-sesamin may be able to interfere with Lon catalytic activity (Wang et al., 2010) . The same study revealed that incubation of cells with (-)-sesamin (50-100 μM) for 30 min induced p53-independent DNA damage responses in NSCLC cells, highlighted by G1/S checkpoint activation and apoptosis. Such events were evident by the enhanced phosphorylation of checkpoint proteins (histone 2A variant X (H2AX), Nijmegen breakage syndrome 1 (NBS1 or nibrin), and checkpoint kinase 2 (CHK2), caspase-3 cleavage, and sub-G1 accumulation (Wang et al., 2010) . Such effects were dose-dependent. In sum, the findings of this study indicate that the pro-apoptotic effects of (-)-sesamin are due to its dual function toward inhibition of Lon and activation of DNA damage checkpoints. A study demonstrated sesamin's successful apoptotic effects against multiple cancer cell lines (KBM-5 cells, A293 cells, H1299 cells, HCT116 cells, and RPMI-8226 cells) (Harikumar et al., 2010) . Harikumar and colleagues demonstrated that sesamin potentiates TNFα-induced apoptosis by suppressing Bcl-2 and survivin, critical promoters of cell survival (Harikumar et al., 2010) . Sesamin-mediated apoptosis was also accompanied by significantly suppressed NF-κB activity. This was attributed to the ability of sesamin to inhibit the degradation of inhibitor of κB (IκBα), the inhibitor of NF-κB, through the suppression of IκBα phosphorylation and down-regulation of IκBα kinase (IKK) activity, leading to inhibited NF-κB phosphorylation and nuclear translocation, and NF-κB-mediated transcriptional activity. Furthermore, sesamin-mediated down-regulation of IKK activity was shown to be due to inhibition of transforming growth factor β-activated kinase 1 (TAK1) (Harikumar et al., 2010) .
In another in vitro study, Deng and colleagues demonstrated that sesamin significantly induces cell cycle arrest and apoptosis in HepG2, a human HCC cell line, with no obvious effect on L02, a human normal liver cell line (Deng et al., 2013) . In a dose-dependent manner, sesamin (25-125 μM) was shown to trigger apoptosis by inducing G2/M phase arrest and suppressing constitutive and IL-6-induced STAT3 signaling pathway in a dose-dependent manner. Suppression of STAT3 signaling by sesamin (25-75 μM) was accompanied by regulation of STAT3-targeted downstream genes including cyclin A, cyclin B1, cell-division cycle 2 (CDC2), p53, p21, Bcl-xL, and Bcl-2. However, sesamin had no effect on the total protein level of JAK2 and STAT3 (Deng et al., 2013) . These findings, similar to those in relation to the pro-apoptotic effects of (+)-episesamin against HCC cells (Freise et al., 2012) , strongly suggest that sesamin can be used as part of an adjuvant chemotherapy to prevent or treat liver cancer. (Fig. 1) 
Anti-inflammatory effects of sesamin
Studies also focused on evaluating the possible anti-inflammatory properties of sesamin using different in vitro and in vivo models. Given that chemokines play critical roles in the pathogenesis of asthmatic inflammation, Hsieh and colleagues performed an in vitro study to evaluate the effects of sesamin on the expression of macrophage-derived chemokines (MDC) in human primary monocytes and THP-1 cells (Hsieh et al., 2014) . After pre-incubation with sesamin (0.01-10 μM) for 2 h, the cells were exposed to LPS as a means of inducing MDC. It was demonstrated that sesamin significantly suppressed LPS-induced expression of interferon γ (IFNγ)-inducible protein 10 (IP-10/CXCL10) in THP-1 cells, but not in human primary monocytes, with no significant effects on LPS-induced expression of TNFα or growth-regulated oncogene α (GROα/CXCL1) in THP-1 and human primary monocytes. Such effects were dose-and time-dependent manner. The inhibitory effect of sesamin against MDC was abrogated by ER and peroxisome proliferator-activated receptor α (PPARα) antagonists, suggesting that ability of sesamin to suppress MDC is mediated by ER and PPARα. Furthermore, sesamin inhibited LPS-induced activation of p38 mitogenactivated protein kinase (p38 MAPK) and NF-κB signaling pathways and acetylation of histone H3/H4 in the promoter region of MDC (Hsieh et al., 2014) . In sum, this study suggests that sesamin mediates its suppressive role against MDC-dependent inflammation via inhibition of pathways involving ER, PPARα, p38 MAPK, and NF-κB, as well as epigenetic regulation. Characterizing the possible various sesaminmediated genetic alterations, other than promoter inhibition, is essential for broadening our understanding of the molecular mechanisms underlying the anti-cancer effects sesamin. In turn, this will enable us to better develop chemotherapeutic approaches, involving sesamin, to prevent and treat various types of cancer. Fig. 1 . A brief summary of the known molecular and cellular mechanisms as well as the major targeted signaling pathways underlying the anti-proliferative, pro-apoptotic, antiinflammatory, anti-metastatic, anti-and pro-angiogenic, and pro-autophagocytic activities of sesamin.
A.F. Majdalawieh et al. European Journal of Pharmacology 815 (2017) 512-521 5. Anti-metastatic effects of sesamin
One important anti-carcinogenic property of sesamin is its protective potential against metastatic events. Evidently, regulating the expression of various proteins involved in metastasis ultimately controls tumor invasion and carcinogenesis. Cellular factors that regulate metastasis include, but not limited to, matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). In an in vitro study, sesamin treatment was shown to be accompanied by a significant reduction in the production of MMP-9 in macrophage-enhanced MCF-7 and MDA-MB-231 human breast cancer cells (Lee et al., 2011) . In another in vitro study using a human chronic myeloid leukemia cell line (KBM-5), sesamin treatment (100 μM) was accompanied by a significant time-dependent reduction in TNFα-induced expression of MMP-9 and intracellular adhesion molecule 1 (ICAM-1) (Harikumar et al., 2010) . In agreement, sesamin (10-100 μg/ml) was shown to significantly inhibit LPS-induced expression of MMP-9 and ICAM-1 in PC3 cells in a dose-dependent manner (Xu et al., 2015) .
Moreover, Freise and colleagues demonstrated that HCC cells treated with (+)-episesamin (10 μM) exhibited significantly suppressed expression and activity of MMP-9, a critical mediator of metastasis that is over-expressed in invasive HCC (Freise et al., 2012) . Additionally, ex vivo analysis revealed that sesamin (100 μM) induced the differentiation of SP cells into E-cadherin-expressing cells, promoting cell-cell contact and attenuating tumor spread (Kong et al., 2014) . It was also demonstrated that sesamin potently suppressed the carcinogenic potential of SP cells with regard to tumor-sphere formation, colony-formation, and Matrigel invasion (Kong et al., 2014) . Such effects were dose-and time-dependent. Collectively, these in vitro and in vivo findings clearly suggest that sesamin possesses potent anti-metastatic properties, potentially allowing it to serve as a therapeutic agent to attenuate tumor metastasis and invasion.
6. Anti-angiogenic and pro-angiogenic effects of sesamin Angiogenesis is one of the key events that promote tumor development. The well-documented anti-cancer effects of sesamin have been attributed, at least partially, to its ability to regulate genes whose products are critically involved in angiogenesis. In an in vitro study, it was demonstrated that (+)-episesamin treatment (10 μM) in HCC cells was accompanied by significantly lower levels of vascular endothelial growth factor (VEGF), a critical mediator of angiogenesis (Freise et al., 2012) . In another in vitro study using a human chronic myeloid leukemia cell line (KBM-5), sesamin treatment (100 μM) was accompanied by a significant time-dependent reduction in TNFα-induced expression of VEGF (Harikumar et al., 2010) . In agreement, Lee and colleagues demonstrated that sesamin treatment (10-100 μM) for 4-24 h significantly suppressed the expression of VEGF in macrophage-enhanced MCF-7 and MDA-MB-231 human breast cancer cells in a dose-and timedependent manner (Lee et al., 2011) . This inhibitory effect was attributed to the ability of sesamin to suppress signaling via HIF-1α, NF-κB, AKT, and p38 MAPK, important transcription factors for VEGF expression (Lee et al., 2011) . Moreover, sesamin (10-100 μg/ml) was shown to significantly inhibit LPS-induced expression of VEGF in PC3 cells in a dose-dependent manner (Xu et al., 2015) .
Conversely, other studies suggest that sesamin can stimulate specific signaling pathways that enhance several angiogenic activities including endothelial cell proliferation, migration, tube formation, and neovascularization. Chung and colleagues provided experimental evidence indicating that sesamin treatment (10-30 μM) for 10-60 min in human umbilical vein endothelial cells (HUVECs) potently activated several angiogenesis-inducing pathways including ERK1/2-, PI3K/AKT/eNOS-, p125(FAK)-, and p38 MAPK-dependent signaling pathways in a doseand time-dependent manner (Chung et al., 2010) . Inhibitors of these pathways indirectly suppressed sesamin-stimulated angiogenesis. Notably, sesamin-mediated angiogenic effects were not accompanied by changes in vascular permeability or expression of VEGF, ICAM-1, or vascular cell adhesion molecule 1 (VCAM-1), suggesting that sesamin stimulates angiogenesis without promoting vascular inflammation (Chung et al., 2010) . The discrepancy in the effects of sesamin on angiogenic events can be attributed to the different experimental conditions of the reported studies including, but not limited to, doses, modes of treatment, cell lines, and detection methods. Taken together, sesamin seems to have both inhibitory and stimulatory angiogenic effects, depending on the signaling pathways that sesamin triggers. Identifying the different signaling pathways that sesamin targets would help us pinpoint and directly regulate pathways that promote anti-angiogenic and tumor-suppressive effects. (Fig. 1) 
Pro-autophagocytic effects of sesamin
Although the role of autophagy in cancer development is not very clear, most studies suggest that autophagic mechanisms may suppress tumor development and help with the prognosis of cancer. The number of studies performed to assess the possible effects of sesamin on autophagy are very scarce. In an in vitro stud, Tanabe and colleagues revealed that sesamin possesses potent tumor-suppressive properties against colorectal cancer cell lines, HT29 and LS180, by inducing autophagy as determined by electron microscopy, Western blotting, and immunofluorescence imaging (Tanabe et al., 2011) . Indeed, sesamin treatment (5-50 μM) for 24-72 h caused dose-and time-dependent induction of autophagy in HT29 and LS180 cells. The autophagic pathway in the tested cancer cells was stimulated by sesamin due to its ability to significantly decrease the levels of phosphorylated ephrin A1 (EphA1) and ephrin B2 (EphB2), receptor tyrosine kinases that bind to membrane-bound ephrin-A family ligands residing on adjacent cells leading to contact-dependent signaling into neighboring cells. Interestingly, inhibitors of EphA1 and EphB2 almost completely abrogated sesamin-induced autophagy and sesamin-induced inhibition of cell viability (Tanabe et al., 2011) . This study suggests that the ability of sesamin to induce autophagy can be implicated in its overall anticancer activity against several cancer cell types. The pro-autophagocytic activity of sesamin can also be attributed to its ability to regulate several signaling pathways including, but not limited to, NF-κB (Akl et al., 2012; Freise et al., 2012; Harikumar et al., 2010; Jeng et al., 2005; Kong et al., 2014; Lee et al., 2009 Lee et al., , 2011 Xu et al., 2015; Zheng et al., 2015) , ERK1/2 (Ahmad et al., 2014; Akl et al., 2012; Chung et al., 2010; Hou et al., 2003b Hou et al., , 2014a Hou et al., , 2014b Hsieh et al., 2011; Li et al., 2016; Ohnishi et al., 2013; Park et al., 2015) , and p38 MAPK (Hou et al., 2003a (Hou et al., , 2014a (Hou et al., , 2014b Hsieh et al., 2011 Hsieh et al., , 2014 Jeng et al., 2005; Lee et al., 2011; Ohnishi et al., 2013; Phitak et al., 2012; Xu et al., 2015) signaling pathways. Needless to say, more in vitro and in vivo studies are definitely needed to shed more light on the ability of sesamin to regulate autophagy and the exact mechanisms underlying sesamin-mediated autophagic events. (Fig. 1 ) Table 1 provides a brief summary about the reported in vitro and in vivo anti-cancer activities of sesamin. Table 2 provides a detailed summary of the main findings related to the anti-cancer activities of sesamin, the experimental models, the dosages, the dosage regimens, and whether the results are dose-and/or time-dependent.
Conclusions
Sesamin demonstrates a wide range of properties that could be used in therapeutic practices. The wide range of experimental research that extensively studied the properties of sesamin concluded that one of its significant therapeutic characteristics is its role as an anti-carcinogen. Some of the properties that render sesamin as an effective anti-carcinogen include anti-proliferative, anti-metastatic, anti-inflammatory, pro-apoptotic, anti-and pro-angiogenic, and pro-autophagocytic activities. Such activities are shown to be effective when subjected to several types of cancer cells including human lung cancer cells and A.F. Majdalawieh et al. European Journal of Pharmacology 815 (2017) 512-521 human breast cancer cells. Sesamin also plays a role in selective signaling pathways that are responsible for cancer cell progression. Some of these prominent pathways are the NF-κB, STAT3, c-Jun N-terminal kinase (JNK), ERK1/2, p38 MAPK, PI3K/AKT, caspase-3, and p53 signaling pathways. Noteworthy, the reported effects of sesamin in cancer cells have also been assessed in non-cancer cell lines. For example, the pro-apoptotic effects of sesamin are not restricted to cancer cells as sesamin has been shown to induce apoptosis in normal INS-1 cells derived from pancreatic beta cells (Zheng et al., 2015) . Sesamin was able to exert apoptotic activity in INS-1 cells that were subjected to streptozotocin, an oxidative stress-inducing agent (Zheng et al., 2015) . Moreover, A detailed summary of the main findings related to the anti-cancer activities of sesamin, the experimental models, the dosages, the dosage regimens, and whether the results are dose-and/or time-dependent. A.F. Majdalawieh et al. European Journal of Pharmacology 815 (2017) 512-521 sesamin has been shown to play protective roles against CCl 4 -induced cytotoxicity in the hepatocytes of male Crlj:CD1 (ICR) mice . In addition, the anti-inflammatory effects that sesamin exerts in cancer cells have also been reported in non-cancer cells. For example, in an in vitro study performed by Li and colleagues, sesamin was shown to significantly inhibit LPS-induced production of IL-1β, TNFα, inducible nitric oxide synthase (iNOS), nitric oxide (NO), COX-2, and prostaglandin E2 (PGE2) in nucleus pulposus (NP) cells, isolated from Sprague-Dawley rats (Li et al., 2016) . Similar findings were reported in LPS-challenged mice (Chavali et al., 1997) . Furthermore, by virtue of its ability to inhibit the expression of MMP-1, MMP-3, and MMP-13, sesamin was shown to protect against papain-induced osteoarthritis (OA) in rats (Phitak et al., 2012) . This study strongly suggests that sesamin can be used a part of an adjuvant chemotherapeutic approach to prevent or treat OA. Moreover, sesamin plays a protective role against steatohepatitis by alleviating levels of MMP-2, MMP-9, TIMP-1, and PPARγ (Periasamy et al., 2014) . This is consistent with the observation that PPARγ signaling in macrophages is enhanced by sesamin and sesame oil in a dose-dependent manner (Majdalawieh and Ro, 2014; Majdalawieh and Ro, 2015) . Several other in vitro and in vivo studies have confirmed the anti-inflammatory activities of sesamin and its metabolites (Akl et al., 2012; Chavali et al., 1997; Freise et al., 2012; Harikumar et al., 2010; Hou et al., 2014b; Jeng et al., 2005; Kong et al., 2014; Lahaie-Collins et al., 2008; Lee et al., 2009 Lee et al., , 2011 Zheng et al., 2015) . Various studies suggest that sesamin can exert potent anti-oxidant activity against non-cancer cells. Indeed, it was demonstrated that sesamin inhibits oxidative stress in non-cancer cells, at least in part, by inhibiting several signaling pathways including MAPK pathway, JNK pathway, and caspase-3 pathway (Ahmad et al., 2014; Hou et al., 2003a Hou et al., , 2003b Hou et al., , 2004 Hou et al., , 2014a Hou et al., , 2014b Jeng et al., 2005; Lee et al., 2009; Liu et al., 2013; Ohnishi et al., 2013) . Sesamin has also been shown to offset oxidative stress induced by Kainic acid and 6-hydroxydopamine (6-OHDA), neurotoxic compounds (Hsieh et al., 2011; Park et al., 2015) . Furthermore, sesamin possesses anti-oxidant properties that enable it to exert protective effects against lipid peroxidation (Ghafoorunissa et al., 2004; Kiso, 2004; Ma et al., 2014) . Indeed, sesamin can effectively offset lipid peroxidation by reducing the accumulation of lipid peroxides in several types of non-cancer cells (Ikeda et al., 2003; Yamashita et al., 2000) . The anti-oxidant properties of sesamin were also assessed in the context of cardiotoxicity using noncancer cells. Su and colleagues specifically examined the potential antioxidant effects of sesamin against doxorubicin (DOX)-induced cardiotoxicity in rat cardiomyocytes . Sesamin was shown to play a protective role against cardiotoxicity by suppressing DOX-induced oxidative stress, inhibiting the production of ROS, and enhancing the expression of Sirt1, a critical regulator of cell survival. As in noncancer cells, sesamin was also reported to exert potent anti-oxidant effects and attenuate oxidative stress in a number of cancer cells including human prostate cancer cell line (PC3 cells) (Xu et al., 2015) .
Effect
There is very limited information pertaining to microarray studies that aim at identifying the molecular target(s) of sesamin in cancer cells. A study conducted by Saeed and colleagues aimed at assessing the sensitivity or resistance of various tumor cells to (-)-sesamin (Saeed et al., 2014) . In that study, the researchers performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarraybased mRNA expression in 55 cell lines of the National Cancer Institute (NCI). (-)-Sesamin was found to significantly the over-expression of ABCB1 and ABCB5 genes in the NCI panel of cancer cells. Given that these genes are critically involved in multidrug resistance (MDR) of many tumors, it is suggested that (-)-sesamin may serve as a successful agent in blocking the role that ABCB1 and ABCB5 play in MDR in many types of cancer. Hence, ABCB1 and ABCB5 are potential molecular targets for sesamin in various cancer cell types. Obviously, further microarray-based expression profile studies are needed to search for more molecular targets of sesamin, especially if such targets do not Sesamin has no effect on basal NF-κB activity A.F. Majdalawieh et al. European Journal of Pharmacology 815 (2017) 512-521 belong to the classical MDR mechanisms toward established anti-cancer chemotherapeutics. Clearly, identification of such novel molecular targets of sesamin will help develop a more effective and accurate sesamin-based chemotherapeutic approach to treat various types of cancer. The pharmacokinetics, pharmacodynamics, bioavailability, and metabolism of sesamin were highlighted in several studies using human subjects and animal models. An extensive study was performed by Peñalvo and colleagues to assess the bioavailability, pharmacokinetics, pharmacodynamics, absorption, and tissue distribution of sesamin in humans (Peñalvo et al., 2005) . To this end, blood and fecal samples were obtained at different time intervals from adult human subjects who, after one week of low-lignan food restriction regime, received a single dose of 50 g sesame seeds. The researchers reported a high interindividual variation in the plasma lignan concentrations and they determined individual pharmacokinetic parameters. The study further revealed that enterolactone is the major metabolite of sesamin. Moreover, it was concluded that sesamin and its metabolites are selectively absorbed through the portal vein and metabolized in the liver through mechanisms that are not fully uncovered. Detailed experimental analyses revealed that sesamin is absorbed with a Cmax of 105 ± 11.7 nM at a Tmax of 1 h, an absorption half-life of 15 min, and an elimination half-life of 2.08 ± 0.58 h, with an AUC (area under the curve) value of 362 ± 92.0 nM/h/L (Peñalvo et al., 2005) . Using Sprague-Dawley rats, Ide and colleagues performed an experiment to assess time-dependent changes in serum concentrations of sesamin and episesamin for a period of 24 h after a single oral dose of lignan-free diet or diet containing 0.2% of the indicated lignans (Ide et al., 2009) . It was found that serum levels of the lignans increased soon after the oral administration, peaked after 7-9 h, and started to gradually decrease with half-life (t 1/ 2 ) values of 4.7 ± 0.2 h and 6.1 ± 0.3 h for sesamin and episesamin, respectively (Ide et al., 2009) . Several lignans of sesame seeds were also examined to determine their free radical scavenging capacity (RSC) and their kinetic behavior using the 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) on a kinetic model (Suja et al., 2004) . The second-order rate constant (k 2 ) was measured for an accurate calculation of RSC. The k 2 value of sesamin was determined to be 0.36 × 10 −5 (Suja et al., 2004) .
It has been demonstrated that sesamin is metabolized to several compounds having the catechol structure in vivo and in vitro by liver microsomes in rats (Nakai et al., 2003) . Indeed, sesamin is metabolized by P450 (CYP2C9) enzymes into sesamin monocatechol (SC-1) (also known as demethylpiperitol), and may be further metabolized by the same enzyme into sesamin dicatechol (SC-2) (Yasuda et al., 2010 (Yasuda et al., , 2011 . Sesamin catechols can be additionally methylated by catechol-O-methyltransferase (COMT) enzymes to produce monomethylated variants, SC-1m (also known as piperitol) and SC-2 m ((1R,2S,5R,6S)-6-(4-hydroxy-3-methoxyphenyl)-2-(3,4-dihydroxyphenyl)-3,7-dioxabicyclo[3,3,0]octane) (Yasuda et al., 2011) . Although SC-1 and SC-2 can activate the Nrf/ARE pathway, monomethylated variants of sesamin cannot (Hamada et al., 2011) . This is an important factor, as this suggests that monomethylated variants (SC-1m and SC-2m) are more competent antioxidants compared to SC-1 and SC-2 (Hamada et al., 2011) . Studies have also shown that sesamin catechols (SC-1 and SC-2) are found in human urine upon oral intake (Moazzami et al., 2007) . Catechols found in human urine are glucuronidated via uridine 5′-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase) (UGT) enzymes (Yasuda et al., 2011) . Sesamin can also be metabolized by intestinal microflora into enterolactone and enterodiol, however, this metabolic pathway occurs at a slower rate compared to metabolism by P450 enzymes (Liu et al., 2006) . Enterolactone and enterodiol are classified as byproducts of a dietary lignan known as enterolignans (Borriello et al., 1985; Saarinen et al., 2000; Heinonen et al., 2001) . In rats, it was shown that sesamin is metabolized into enterolignans at a very low rate (1.1%) (Liu et al., 2006) . A separate study on mice demonstrated that sesamin can be metabolized into enterodiol at a higher rate than enterolactone, with a 6.5-8.0 nM enterolactone in serum and 388-569 nM enterodiol (Peñalvo et al., 2006) . Of note, Ide and colleagues suggested that sesamin and its derivatives may also be metabolized to yet other compounds that are distinct in structure from the parent molecules (Ide et al., 2009 ). Yasuda and Sakaki thoroughly reviewed the mechanisms involved in the metabolism of sesamin in the human liver (Yasuda and Sakaki, 2012) . More experiments are needed to further investigate the pharmacokinetics, pharmacodynamics, absorption, bioavailability, tissue distribution, and metabolism of sesamin and its derivatives. Such studies will surely shed more light on the pharmacological, physiological, and nutritional significance of sesamin ingestion. Undoubtedly, future in vitro and in vivo studies will strengthen our understanding of the molecular targets and mechanisms triggered by sesamin, and we anticipate that sesamin will be used as an effective chemotherapeutic anti-carcinogenic agent in the treatment of various types of cancer.
